Biovica International
19.11.2021 16:17:02 CET | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / November 19, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)
Biovica, active in cancer diagnostics, today announced that results from three different studies using DiviTum®TKa, including a budget impact model, will be presented at the world's largest breast cancer symposium, San Antonio Breast Cancer Symposium (SABCS), in early December. The studies are of a next generation CDK inhibitor, samuraciclib from Carrick Therapeutics, the biomarker study PROMISE performed at the Mayo Clinic, and the DiviTum®TKa budget impact model. All studies focused on the role of DiviTum®TKa in monitoring treatment in women with metastatic breast cancer.
Biovica and Carrick Therapeutics have collaborated on generating TK activity (TKa) data in the phase 1/2A study of samuraciclib (NCT033638939), a first-in-class, oral, selective inhibitor of CDK7 that recently received fast track designation from the US Food and Drug Administration (FDA). The study demonstrates the potential association of TKa levels with treatment effect for this next generation CDK inhibitor.
P1-18-10 A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
DiviTum®TKa results from the clinical study PROMISE (NCT03281902) conducted at the Mayo Clinic show the association of TKa with progression free survival. The study results are a continuation of the results presented on SABCS 2020. Since then, the study has continued and samples from almost twice as many patients have been tested for TKa, with the new results confirming the initial analysis and earlier DiviTum®TKa results - i.e., the usage of DiviTum®TKa as a valuable tool in the evaluation of treatment effect in metastatic breast cancer.
P5-13-22 Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)
Additional results of the healthcare DiviTum®TKa Budget Impact Model show the potential for DiviTum®TKa to substantially reduce the number of CT scans and bone scans used in monitoring women with metastatic breast cancer. As these scans are both costly and a burden on patients, this reinforces the potential benefit of DiviTum®TKa to healthcare systems and to patients. Additionally, the test may enable early identification when a treatment is not effective and therefore enable overall savings of three times the added spend on the DiviTum®TKa test.
P3-03-05 The budget impact of the DiviTum®TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer
"The data on DiviTum®TKa being presented at SABCS strengthens the scientific and economic foundation for the role of the test in the care of breast cancer patients. We are very pleased with these results," said Anders Rylander, CEO of Biovica.
The San Antonio Breast Cancer Symposium, SABCS, runs December 7-10, 2021.
Contact:
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.
Attachments
Biovica's DiviTum®TKa in three studies at SABCS 2021
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/673809/Biovicas-DiviTumRTKa-in-Three-Studies-at-SABCS-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Akkodis and Hamburg Public Transport Association Showcase hvv mia at InnoTrans 2026, Demonstrating the Future of AI-Powered Mobility22.9.2026 06:45:00 CEST | Press release
BERLIN, DE / ACCESS Newswire / September 22, 2026 / Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, will showcase how artificial intelligence is helping transform passenger mobility at InnoTrans 2026, the world's leading international trade fair for transport technology. Headlining Akkodis' presence is hvv mia, one of Akkodis' Synergeticon solutions, developed in collaboration with Hamburg Public Transport Association (hvv) to create more seamless, accessible and connected passenger experiences. Together, Akkodis and hvv will demonstrate how AI can help transportation operators better serve passengers while advancing the digital transformation of rail and other transportation networks. Built on Akkodis' Synergeticon AI Conversational Service Hub, hvv mia is a real-world example of how conversational and agentic AI can connect information, services and transactions across transportation systems through a single natural-language interface. Develop
FQ-42 Vengeance Finds New Home at Creech Air Force Base21.9.2026 17:00:00 CEST | Press release
SAN DIEGO, CA / ACCESS Newswire / September 21, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) congratulates the U.S. Air Force (USAF) on the pace of progress for its Collaborative Combat Aircraft program, which features the FQ-42 Vengeance designed and produced by GA-ASI. The latest milestone took place Sept. 18, when a new FQ-42 Vengeance was delivered to Creech AFB, Nev., to continue operations with test and evaluation units. "The CCA program's rate of progress has been incredible," said Mike Atwood, GA-ASI Vice President of Advanced Programs. "Every week, the Air Force is pushing forward with new and more impressive accomplishments using Vengeance. It's amazing to think of how far this program has come in such a short amount of time." The FQ-42 that arrived at Creech will continue regular test and evaluation operations with the Air Force aimed at experimentation with the new aircraft. Previous efforts with Vengeance and other GA-ASI jets, including XQ-67A Off-Board Sens
Datavault AI and Cutting-Edge Sports Management Announce Dream Bowl XV at AT&T Stadium and Launch First-of-Its-Kind Bowl Combine21.9.2026 15:45:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / September 21, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced Dream Bowl XV. The game is the 15th anniversary edition of the premier college football all-star showcase for professional draft-eligible talent from all college divisions and NAIA programs. It will be held Sunday, January 17, 2027, at AT&T Stadium in Arlington, Texas, and is planned to be broadcast nationally on ESPN. Dream Bowl XV continues Datavault AI's role as an intellectual property licensing partner and official sponsor of The Dream Bowl alongside Cutting-Edge Sports Management. It builds on the Company's debut at Dream Bowl XIV. Since 2013, The Dream Bowl has honored the legacy of Dr. Martin Luther King Jr. and has given overlooked collegiate athletes a professional-caliber send-off in front of professional scouts. N
Winners of this Year's Semmelweis-Richter International Journalism Award Announced21.9.2026 14:05:00 CEST | Press release
BUDAPEST I. KERÜLET, HU / ACCESS Newswire / September 21, 2026 / For the second time, Semmelweis University, with the support of Gedeon Richter, has recognized outstanding health and science journalism from across Europe through the Semmelweis-Richter Journalism Award. Six entries received awards in the "Women's Health" and "Pharmaceutical Strategies and Innovation" categories. The first prizes in the two categories were awarded to an international investigative project on abortion and an article about a technology that uses miniature bioengineered devices to mimic the functions of human organs. The competition received around 60 entries from nearly 20 countries. The Semmelweis-Richter Journalism Award was established to recognize high-quality health and science journalism in Europe. As last year, the competition attracted entries from journalists working for major international media outlets, including The Guardian, the Financial Times, The Times, BBC News, Süddeutsche Zeitung and Púb
NOVELIC Partners with Global DMS Leader Smart Eye to Develop Next-Generation Camera and Radar In-Cabin Monitoring Systems21.9.2026 08:00:00 CEST | Press release
BELGRADE, RS / ACCESS Newswire / September 21, 2026 / NOVELIC, a Belgrade-based innovator in mmWave radar solutions, announced a strategic partnership with Smart Eye, a global leader in Driver Monitoring Systems (DMS) and Interior Sensing AI, to provide OEMs with a well-rounded feature set that satisfies the upcoming Euro NCAP requirements for driver and occupant monitoring. The result is a scalable and cost-effective solution that combines vision and radar for straightforward integration. Since the software is running entirely on the sensor, only a single CAN-Bus interface to the vehicle is required, eliminating the need for external hardware, LVDS interfaces, and added computational load elsewhere in the car. NOVELIC and Smart Eye's innovative system approach will debut at Smart Eye's booth #305 at InCabin Europe 2026 in Barcelona. The demonstration will showcase enhanced performance and compliance with relevant safety protocols through the fusion of radar and vision technologies. NO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom